Administration of the bacterial extract Broncho-Vaxom® enhances radiation recovery and myelopoietic regeneration

Fedoročko, Peter; Macková, N; Brezáni, P; Kopka, Michał

doi:10.1016/0162-3109(94)90032-9

Cited by 6 publications

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This process may thus be one of the mechanisms leading to earlier hemopoietic recovery after irradiation (26,27). BV-mediated radioprotection has been demonstrated to accelerate the regeneration of not only peripheral blood cells but also endoCFU-S and femoral CFU-S and GM-CFC (11,13).…”

Section: Discussionmentioning

confidence: 99%

“…Our previous studies demonstrated that BV injection before irradiation increased the number of endogenous colony-forming units (endoCFU-S) in Combined radiopro tec tion sublethally irradiated mice and increased the number of mice that survived beyond 30 days after lethal irradiation (1 1, 12). Also, BV-injection accelerated early recovery of hemopoietic stem cells and cells in the peripheral blood (13,14). BV administered in combination with WR-272 1 better enhances survival and also more effectively accelerates post-irradiation hemopoietic recovery than either agent administered alone (15).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Radioprotective effects of combination broncho‐vaxom, a macrophage activator, and indomethacin, an inhibitor of prostaglandin production: relationship to myelopoiesis

Fedoročko

Macková

1996

European J of Haematology

View full text Add to dashboard Cite

The effects of the bacterial extract broncho‐vaxom (BV; radioprotective immunomodulator; 500 μg/mouse i.p., 24 h) and indomethacin (INDO; inhibitor of prostaglandin production; 2 times 40 μg/mouse i.m., ‐ 24 h and ‐ 3 h) on the post‐irradiation recovery of hemopoietic functions in mice were investigated. Both agents were administered either alone or in combination. Endogenous spleen colony formation was increased in all treatment groups, with combination‐treated mice exhibiting the greatest effects. Similarly, 24 h after combined administration of BV and INDO (i.e. at the time of presumed irradiation) to the non‐irradiated mice granulocyte‐macrophage colony‐forming cell (GM‐CFC) numbers were greater in the bone marrow and spleen. Also, as determined by hydroxyurea injection, there was an increase in the number of GM‐CFC in the S‐phase of the cell cycle in the bone marrow. However, GM‐CFC in the spleen of combination pretreated mice was not stimulated to significant proliferation as compared to GM‐CFC in the spleen of mice injected with BV alone. Combined modality treatment was also more effective than single agent treatments in accelerating bone marrow cellularity and GM‐CFC regeneration, but not in accelerating GM‐CFC regeneration in the spleen. Combined administration of BV and INDO to mice prior to lethal irradiation exerted an additional radioprotective effect and protected 95% of the C57B1/6 mice.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Radioprotective effects of combination broncho‐vaxom, a macrophage activator, and indomethacin, an inhibitor of prostaglandin production: relationship to myelopoiesis

Fedoročko

Macková

1996

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…It has been shown to significantly enhance post-irradiation survival in several mouse strains [ 55 ]. Subsequent studies have revealed positive hematological effects of Broncho-Vaxom ® in sublethally irradiated mice [ 56 , 57 , 58 ]. Broncho-Vaxom ® has been also tested with success in its combined administration with the chemical radioprotector WR-2721 (amifostine) [ 59 , 60 ].…”

Section: Immunomodulatorsmentioning

confidence: 99%

“…Broncho-Vaxom ® has been also tested with success in its combined administration with the chemical radioprotector WR-2721 (amifostine) [ 59 , 60 ]. Broncho-Vaxom ® has been found to act radioprotectively when administered pre-irradiation [ 55 , 56 , 57 , 58 , 59 , 60 ], as well as a radiomitigator following its post-irradiation administration [ 60 ]. In a later study, Broncho-Vaxom ® has been administered to rats in repeated injections comprising one pre-irradiation dose and repeated post-irradiation doses in the course of a three-week period of fractionated irradiation.…”

Section: Immunomodulatorsmentioning

confidence: 99%

Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?

Höfer

Hoferová

Falk

2017

IJMS

View full text Add to dashboard Cite

In recent times, cytokines and hematopoietic growth factors have been at the center of attention for many researchers trying to establish pharmacological therapeutic procedures for the treatment of radiation accident victims. Two granulocyte colony-stimulating factor-based radiation countermeasures have been approved for the treatment of the hematopoietic acute radiation syndrome. However, at the same time, many different substances with varying effects have been tested in animal studies as potential radioprotectors and mitigators of radiation damage. A wide spectrum of these substances has been studied, comprising various immunomodulators, prostaglandins, inhibitors of prostaglandin synthesis, agonists of adenosine cell receptors, herbal extracts, flavonoids, vitamins, and others. These agents are often effective, relatively non-toxic, and cheap. This review summarizes the results of animal experiments, which show the potential for some of these untraditional or new radiation countermeasures to become a part of therapeutic procedures applicable in patients with the acute radiation syndrome. The authors consider β-glucan, 5-AED (5-androstenediol), meloxicam, γ-tocotrienol, genistein, IB-MECA (N6-(3-iodobezyl)adenosine-5’-N-methyluronamide), Ex-RAD (4-carboxystyryl-4-chlorobenzylsulfone), and entolimod the most promising agents, with regards to their contingent use in clinical practice.

show abstract

“…Positive therapeutical outcomes, manifested as an enhancement of murine hematopoiesis after radiation damage, were reported when NSAIDs (indomethacin, diclofenac, or flurbiprofen) were administered before [32,33,34,35] or after irradiation [36,37,38], as well as when given to mice exposed to fractionated irradiation [39,40,41], to continuously irradiated rats [42], or lethally irradiated mice who received syngeneic bone marrow transplantation [43,44]. Administration of diclofenac was found to stimulate hematopoiesis also in tumor-bearing mice [45] and NSAIDs were observed to improve the processes of hematopoietic regeneration following exposures of experimental mice to ionizing radiation when administered concomitantly with immunomodulators glucan [46,47], muramyl tripeptide phosphatidylethanolamine [48,49,50], or broncho-vaxom [51,52], as well as with chemical radioprotectors cystamine or WR-2721 [53,54,55,56]. An improvement of hematopoietic recovery after administration of non-selective cyclooxygenase inhibitors was also observed in mice whose bone marrow was damaged by cytotoxic anti-tumor drugs [57,58,59].…”

Section: Action Of Non-selective Cyclooxygenase Inhibitors On Hemamentioning

confidence: 99%

Stimulatory Action of Cyclooxygenase Inhibitors on Hematopoiesis: A Review

et al. 2012

View full text Add to dashboard Cite

Abstract:The presented review summarizes experimental data obtained with a mouse model when investigating the relationship between inhibition of prostaglandin production and hematopoiesis. While prostaglandin E 2 acts in a negative feedback control of myelopoiesis, inhibition of cyclooxygenases, responsible for its production, shifts the feedback to positive control. Based on these relationships, agents inhibiting cyclo-oxygenases, known as non-steroidal anti-inflammatory drugs (NSAIDs), can activate hematopoiesis and be protective or curative under myelosuppressive states. The effectiveness of therapeutic use of NSAIDs in these situations is expressive especially under the selective inhibition of cyclooxygenase-2 (COX-2), when undesirable side effects of cyclooxygenase-1 inhibition, like gastrointestinal damage, are absent. The effects of the clinically approved selective COX-2 inhibitor, meloxicam, were investigated and demonstrated significant hematopoiesis-stimulating and survival-enhancing actions of this drug in sublethally or lethally γ-irradiated mice. These effects were connected with the ability of meloxicam to increase serum levels of the granulocyte colony-stimulating factor. It can be inferred from these findings that selective COX-2 inhibitors might find their use in the treatment of myelosuppressions of various etiologies.

show abstract

Administration of the bacterial extract Broncho-Vaxom® enhances radiation recovery and myelopoietic regeneration

Cited by 6 publications

References 20 publications

Radioprotective effects of combination broncho‐vaxom, a macrophage activator, and indomethacin, an inhibitor of prostaglandin production: relationship to myelopoiesis

Radioprotective effects of combination broncho‐vaxom, a macrophage activator, and indomethacin, an inhibitor of prostaglandin production: relationship to myelopoiesis

Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?

Stimulatory Action of Cyclooxygenase Inhibitors on Hematopoiesis: A Review

Contact Info

Product

Resources

About